Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 986 | 1001 | 1018 | 916 | 1004 | 1157 |
Fund Return | -1.37% | 0.07% | 1.79% | -2.89% | 0.08% | 1.47% |
Place in category | 209 | 240 | 175 | 105 | 128 | 55 |
% in Category | 47 | 55 | 41 | 30 | 33 | 23 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Principal LifeTime 2030 Institution | 3.81B | 4.23 | 1.43 | 6.41 | ||
Principal High Yield Fund I Inst | 3.59B | 2.00 | 1.85 | 3.37 | ||
Principal LifeTime 2040 Institution | 3.33B | 6.11 | 2.65 | 7.48 | ||
Principal LifeTime 2050 Institution | 2.58B | 7.47 | 3.52 | 8.12 | ||
Principal Short-Term Income Inst | 2.54B | 1.50 | 0.93 | 1.84 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Total Bond Market II Index | 147.63B | -1.55 | -3.06 | 1.22 | ||
Vanguard Total Bond Market II Idx I | 139.73B | -1.57 | -3.13 | 1.15 | ||
Vanguard Total Bond Market Index Ad | 97.34B | -1.55 | -3.06 | 1.25 | ||
Fidelity US Bond Index Instl Prem | 56.54B | -1.64 | -3.12 | 1.22 | ||
Baird Aggregate Bond Inst | 45.59B | -1.15 | -2.76 | 1.67 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
AbbVie Inc. 5.05% | - | 0.57 | - | - | |
Fifth Third Bancorp 2.375% | - | 0.56 | - | - | |
Biogen Inc 2.25% | - | 0.52 | - | - | |
Truist Bank (North Carolina) 2.636% | - | 0.48 | - | - | |
PPL Electric Utilities Corporation 5.25% | - | 0.48 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Sell |
Technical Indicators | Strong Buy | Strong Buy | BUY |
Summary | Strong Buy | Strong Buy | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review